Literature DB >> 25542213

Cullin 4A and 4B ubiquitin ligases interact with γ-tubulin and induce its polyubiquitination.

Anand Thirunavukarasou1, Gokulapriya Govindarajalu, Prachi Singh, Venkateshwarlu Bandi, Kannan Muthu, Sudhakar Baluchamy.   

Abstract

Regulated polyubiquitination is a key step for controlling protein degradation and maintaining proper balance between the proliferation of normal and uncontrolled cells. Addition of ubiquitin to the proteins by E3 ubiquitin ligases targets them for degradation by the 26S proteosome machinery. Discrepancies in ubiquitination and/or proteosome degradation might lead to multiple genetic disorders in humans. It is reported that CUL1 and BRCA1 ubiquitin ligases localize on centrosome region and regulate the centrosome duplication cycle for genomic stability. In the current study, we predicted the possible interaction of E3 ubiquitin ligase CUL4A complex with γ-tubulin, a centrosome-specific protein, using bioinformatic protein-protein docking analysis. We also confirmed their interaction by performing co-immunoprecipitation studies using endogenous CUL4A/B and stable cell lines that overexpress Flag-CUL4A or Flag-CUL4B. We additionally noted that the γ-tubulin was polyubiquitinated by CUL4A or 4B immune complex indicating that CUL4A or CUL4B may regulate the stability of γ-tubulin. Furthermore, the inhibition of proteosomal degradation pathway using MG132 or LLNV drugs resulted in accumulation and co-localization of CUL4A with γ-tubulin in the centrosome region. Overall, our observation has identified γ-tubulin as a novel target for E3 ubiquitin ligase CUL4 complex, and might lead to the establishment of a unique mechanism for controlling centrosome stability.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25542213     DOI: 10.1007/s11010-014-2309-7

Source DB:  PubMed          Journal:  Mol Cell Biochem        ISSN: 0300-8177            Impact factor:   3.396


  50 in total

1.  BRCA1-dependent ubiquitination of gamma-tubulin regulates centrosome number.

Authors:  Lea M Starita; Yuka Machida; Satish Sankaran; Joshua E Elias; Karen Griffin; Brian P Schlegel; Steven P Gygi; Jeffrey D Parvin
Journal:  Mol Cell Biol       Date:  2004-10       Impact factor: 4.272

2.  Glide: a new approach for rapid, accurate docking and scoring. 1. Method and assessment of docking accuracy.

Authors:  Richard A Friesner; Jay L Banks; Robert B Murphy; Thomas A Halgren; Jasna J Klicic; Daniel T Mainz; Matthew P Repasky; Eric H Knoll; Mee Shelley; Jason K Perry; David E Shaw; Perry Francis; Peter S Shenkin
Journal:  J Med Chem       Date:  2004-03-25       Impact factor: 7.446

3.  The molecular basis of CRL4DDB2/CSA ubiquitin ligase architecture, targeting, and activation.

Authors:  Eric S Fischer; Andrea Scrima; Kerstin Böhm; Syota Matsumoto; Gondichatnahalli M Lingaraju; Mahamadou Faty; Takeshi Yasuda; Simone Cavadini; Mitsuo Wakasugi; Fumio Hanaoka; Shigenori Iwai; Heinz Gut; Kaoru Sugasawa; Nicolas H Thomä
Journal:  Cell       Date:  2011-11-23       Impact factor: 41.582

4.  How good is automated protein docking?

Authors:  Dima Kozakov; Dmitri Beglov; Tanggis Bohnuud; Scott E Mottarella; Bing Xia; David R Hall; Sandor Vajda
Journal:  Proteins       Date:  2013-10-17

5.  A family of diverse Cul4-Ddb1-interacting proteins includes Cdt2, which is required for S phase destruction of the replication factor Cdt1.

Authors:  Jianping Jin; Emily E Arias; Jing Chen; J Wade Harper; Johannes C Walter
Journal:  Mol Cell       Date:  2006-09-01       Impact factor: 17.970

Review 6.  Ubiquitin and ubiquitin-like proteins as multifunctional signals.

Authors:  Rebecca L Welchman; Colin Gordon; R John Mayer
Journal:  Nat Rev Mol Cell Biol       Date:  2005-08       Impact factor: 94.444

Review 7.  The ubiquitin system.

Authors:  A Hershko; A Ciechanover
Journal:  Annu Rev Biochem       Date:  1998       Impact factor: 23.643

8.  TFDP1, CUL4A, and CDC16 identified as targets for amplification at 13q34 in hepatocellular carcinomas.

Authors:  Kohichiroh Yasui; Shigeki Arii; Chen Zhao; Issei Imoto; Masakazu Ueda; Hisaki Nagai; Mitsuru Emi; Johji Inazawa
Journal:  Hepatology       Date:  2002-06       Impact factor: 17.425

9.  DDB1 targets Chk1 to the Cul4 E3 ligase complex in normal cycling cells and in cells experiencing replication stress.

Authors:  Van Leung-Pineda; Jiwon Huh; Helen Piwnica-Worms
Journal:  Cancer Res       Date:  2009-03-10       Impact factor: 12.701

10.  Gamma-tubulin is present in Drosophila melanogaster and Homo sapiens and is associated with the centrosome.

Authors:  Y Zheng; M K Jung; B R Oakley
Journal:  Cell       Date:  1991-05-31       Impact factor: 41.582

View more
  6 in total

1.  N-terminal truncations of human bHLH transcription factor Twist1 leads to the formation of aggresomes.

Authors:  Gokulapriya Govindarajalu; Murugan Selvam; Elango Palchamy; Sudhakar Baluchamy
Journal:  Mol Cell Biochem       Date:  2017-08-04       Impact factor: 3.396

2.  miR-181a-2 downregulates the E3 ubiquitin ligase CUL4A transcript and promotes cell proliferation.

Authors:  Venkateshwarlu Bandi; Sudhakar Baluchamy
Journal:  Med Oncol       Date:  2017-07-20       Impact factor: 3.064

Review 3.  The preclinical discovery and development of bortezomib for the treatment of mantle cell lymphoma.

Authors:  Richard Arkwright; Tri Minh Pham; Jeffrey A Zonder; Q Ping Dou
Journal:  Expert Opin Drug Discov       Date:  2016-12-20       Impact factor: 6.098

4.  Cullin E3 Ligase Activity Is Required for Myoblast Differentiation.

Authors:  Jordan Blondelle; Paige Shapiro; Andrea A Domenighetti; Stephan Lange
Journal:  J Mol Biol       Date:  2017-02-24       Impact factor: 5.469

Review 5.  γ-Tubulin in microtubule nucleation and beyond.

Authors:  Vadym Sulimenko; Eduarda Dráberová; Pavel Dráber
Journal:  Front Cell Dev Biol       Date:  2022-09-01

Review 6.  The emerging role for Cullin 4 family of E3 ligases in tumorigenesis.

Authors:  Ji Cheng; Jianping Guo; Brian J North; Kaixiong Tao; Pengbo Zhou; Wenyi Wei
Journal:  Biochim Biophys Acta Rev Cancer       Date:  2018-12-30       Impact factor: 10.680

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.